Zacks: CHF Solutions (CHFS) Given Consensus Rating of “Strong Buy” by Analysts

CHF Solutions (NASDAQ:CHFS) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus target price of $15.00 for the company, according to Zacks. Zacks has also given CHF Solutions an industry rank of 146 out of 265 based on the ratings given to its competitors.

Several equities analysts have recently issued reports on the stock. ValuEngine raised shares of CHF Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Zacks Investment Research cut shares of CHF Solutions from a “hold” rating to a “sell” rating in a research note on Tuesday, March 27th.



Shares of CHF Solutions traded down $0.02, hitting $2.89, during mid-day trading on Friday, according to Marketbeat. The company’s stock had a trading volume of 135,046 shares, compared to its average volume of 542,747. The stock has a market capitalization of $12.47 million, a P/E ratio of -0.08 and a beta of 2.24. CHF Solutions has a fifty-two week low of $2.50 and a fifty-two week high of $32.60.

CHF Solutions (NASDAQ:CHFS) last announced its quarterly earnings data on Tuesday, May 8th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.47). The business had revenue of $1.04 million during the quarter. CHF Solutions had a negative return on equity of 154.04% and a negative net margin of 455.30%. equities research analysts forecast that CHF Solutions will post -2.09 earnings per share for the current fiscal year.

CHF Solutions Company Profile

CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. The company focuses on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Get a free copy of the Zacks research report on CHF Solutions (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply